Get the Stockscreener App
208.09
3.79%
7.59
Ascendis Pharma A S Adr stock is traded at $208.09, with a volume of 470.02K.
It is up +3.79% in the last 24 hours and down -0.07% over the past month.
Ascendis Pharma AS is a biopharmaceutical company that applies its TransCon technology platform to make a meaningful difference for patients. The firm's product pipeline includes Endocrinology and Oncology which includes TransCon PTH, TransCon CNP, and others. It operates in North America, Europe, and Rest of the world and derives the majority of its revenue from North America.
See More
Previous Close:
$200.50
Open:
$198.6
24h Volume:
470.02K
Relative Volume:
0.98
Market Cap:
$12.71B
Revenue:
$534.57M
Net Income/Loss:
$-293.67M
P/E Ratio:
-41.89
EPS:
-4.968
Net Cash Flow:
$-187.10M
1W Performance:
-0.91%
1M Performance:
-0.07%
6M Performance:
+19.81%
1Y Performance:
+58.84%
1-Day Range:
$198.60
$209.45
1-Week Range:
$198.30
$214.79
52-Week Range:
$118.03
$223.19
Ascendis Pharma A S Adr Stock (ASND) Company Profile
Name
Ascendis Pharma A S Adr
Sector
Industry
Phone
-
Address
-
Compare ASND with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ASND
Ascendis Pharma A S Adr
|
208.09 | 12.25B | 534.57M | -293.67M | -187.10M | -4.968 |
|
VRTX
Vertex Pharmaceuticals Inc
|
457.26 | 117.50B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
722.83 | 76.06B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
464.56 | 62.53B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
916.31 | 56.75B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
205.04 | 44.10B | 447.02M | -1.18B | -906.14M | -6.1812 |
Ascendis Pharma A S Adr Stock (ASND) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-18-25 | Initiated | Wolfe Research | Peer Perform |
| Oct-17-25 | Initiated | Raymond James | Strong Buy |
| Jul-03-25 | Resumed | Morgan Stanley | Overweight |
| May-05-25 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Apr-16-25 | Initiated | RBC Capital Mkts | Outperform |
| Jan-07-25 | Initiated | UBS | Buy |
| Sep-05-24 | Upgrade | Oppenheimer | Perform → Outperform |
| Jun-25-24 | Upgrade | TD Cowen | Hold → Buy |
| May-31-24 | Initiated | Stifel | Buy |
| Dec-20-23 | Initiated | Jefferies | Buy |
| Jun-14-23 | Resumed | Credit Suisse | Neutral |
| Apr-05-23 | Downgrade | Oppenheimer | Outperform → Perform |
| Apr-04-23 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Apr-03-23 | Downgrade | Credit Suisse | Outperform → Neutral |
| Oct-20-22 | Initiated | Goldman | Buy |
| Aug-30-22 | Resumed | Berenberg | Buy |
| Mar-28-22 | Resumed | Wedbush | Outperform |
| Mar-15-22 | Upgrade | BofA Securities | Neutral → Buy |
| Mar-01-22 | Initiated | Citigroup | Buy |
| Feb-14-22 | Upgrade | Oppenheimer | Perform → Outperform |
| Jan-06-22 | Initiated | Cowen | Market Perform |
| Dec-08-21 | Initiated | Wells Fargo | Overweight |
| Oct-20-21 | Downgrade | BofA Securities | Buy → Neutral |
| Mar-30-21 | Downgrade | Oppenheimer | Outperform → Perform |
| Mar-11-21 | Resumed | Stifel | Buy |
| Dec-17-20 | Initiated | Berenberg | Buy |
| Sep-14-20 | Resumed | JP Morgan | Overweight |
| Mar-20-20 | Initiated | Oppenheimer | Outperform |
| Oct-11-19 | Initiated | Morgan Stanley | Overweight |
| Mar-25-19 | Initiated | Evercore ISI | Outperform |
| Jan-24-19 | Initiated | Cantor Fitzgerald | Overweight |
| Jan-24-19 | Upgrade | Leerink Partners | Mkt Perform → Outperform |
| Jun-26-18 | Initiated | Stifel | Buy |
| Apr-02-18 | Reiterated | Leerink Partners | Mkt Perform |
| May-11-17 | Initiated | JP Morgan | Overweight |
| Mar-09-17 | Downgrade | Leerink Partners | Outperform → Mkt Perform |
| Feb-09-17 | Initiated | Credit Suisse | Outperform |
| Sep-26-16 | Initiated | Wedbush | Outperform |
View All
Ascendis Pharma A S Adr Stock (ASND) Latest News
The time has not yet come to remove your chips from the table: Ascendis Pharma A/S ADR (ASND) - Setenews
Ascendis Pharma Hit By FDA Delay As TransCon CNP Decision Slips To 2026 - sahmcapital.com
Ascendis Pharma Reports Third Quarter 2025 Financial Results - Sahm
Is the Market Bullish or Bearish on Ascendis Pharma AS? - sahmcapital.com
Ascendis Announces Extension of FDA Review Period for TransCon CNP (navepegritide) for Children with Achondroplasia - GlobeNewswire Inc.
Ascendis Announces Extension of FDA Review Period for TransCon CNP (navepegritide) for Children with Achondroplasia - sahmcapital.com
Ascendis Pharma ADR Clears Technical Benchmark, Hitting 90-Plus RS Rating - MSN
ASND | Ascendis Pharma A/S ADR SEC Filings - MarketWatch
European ADRs Slip As Gains And Losses Balance Out - Finimize
Take off with Ascendis Pharma A/S ADR (ASND): Get ready for trading - Setenews
Ascendis Pharma Likely To Report Narrower Q3 Loss; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call - sahmcapital.com
Are These 4 Biotech Stocks Set to Beat Q3 Earnings Estimates? - TradingView
Apple Upgraded, DraftKings Downgraded: Updated Rankings on Top Blue-Chip Stocks - InvestorPlace
Stocks Showing Rising Market Leadership: Ascendis Pharma ADR Earns 81 RS Rating - MSN
New Pooled 3-Year Analysis Confirms Sustained, Clinically Meaningful Improvements in Renal Function for TransCon® PTH (Palopegteriparatide)-Treated Adults with Hypoparathyroidism - Sahm
Should Positive Three-Year TransCon PTH Data Prompt Action From Ascendis Pharma (ASND) Investors? - Sahm
Ascendis Pharma to Report Third Quarter 2025 Financial Results and Provide Business Update on November 12, 2025 - Sahm
3-Year Renal Data in Adults with Hypoparathyroidism Treated with TransCon® PTH (Palopegteriparatide) to Be Shared at Kidney Week 2025 - Sahm
Here's How Much You Would Have Made Owning Ascendis Pharma Stock In The Last 10 Years - Sahm
eBay Upgraded, Meta Platforms Downgraded: Updated Rankings on Top Blue-Chip Stocks - InvestorPlace
Ascendis Pharma (NasdaqGS:ASND): Evaluating Valuation as Analyst Confidence Rises on Key EMA Filing - Sahm
Looking Into Ascendis Pharma AS's Recent Short Interest - Sahm
How Ascendis Pharma’s (ASND) TransCon CNP EMA Submission Has Shaped Its Rare Disease Investment Story - Sahm
Should Investors Consider Ascendis Pharma After FDA Nod for Next-Gen Hormone Therapy in 2025? - Sahm
Raymond James initiates Ascendis Pharma stock with Strong Buy rating - Investing.com
Ascendis Pharma A/S Sponsored ADR (ASND) Stock Price Today | Live Chart & News - Traders Union
Brokerages Set Ascendis Pharma A/S (NASDAQ:ASND) Target Price at $244.64 - Defense World
Walt Disney Upgraded, Southwest Airlines Downgraded: Updated Rankings on Top Blue-Chip Stocks - InvestorPlace
Book value per share of Ascendis Pharma A/S Sponsored ADR – MUN:A71 - TradingView
Ascendis Pharma (ASND) Is Up 6.9% After EMA Filing for TransCon CNP in Achondroplasia Treatment - Sahm
Ascendis Submits Marketing Authorisation Application to the European Medicines Agency for TransCon® CNP for Treatment of Children with Achondroplasia - Sahm
Does Analyst Backing of Yorvipath Shift the Competitive Narrative for Ascendis Pharma (ASND)? - Sahm
Ascendis Pharma increases share capital following warrant exercises - Investing.com
Earnings call transcript: Ascendis Pharma Q2 2025 beats EPS forecasts - Investing.com
Ascendis Pharma A/S Q2 Earnings Call Highlights Growth - The Globe and Mail
Stocks To Watch: Sociedad Quimica ADR Sees Relative Strength Rating Rise To 80 - inkl
Biotech Stocks To Watch And Pharma Industry News - Investor's Business Daily
Stocks To Watch: Ascendis Pharma ADR Sees RS Rating Rise To 92 - Investor's Business Daily
Ascendis Pharma AS earnings beat by €0.45, revenue topped estimates - Investing.com
Ascendis Pharma stock rating reiterated by Cantor Fitzgerald ahead of Q2 results - Investing.com
Ascendis Pharma ADR Shows Rising Price Performance With Jump To 81 RS Rating - Investor's Business Daily
Analysts Offer Insights on Healthcare Companies: Ascendis Pharma (ASND), BioNTech SE (BNTX) and Galapagos (GLPG) - The Globe and Mail
Ascendis Pharma stock jumps after FDA approves SKYTROFA for adult GHD - Investing.com
Stocks Showing Rising Market Leadership: Gpo Aeroportuario ADR Earns 83 RS Rating - inkl
Ascendis Pharma reports positive results from hypothyroid trial - MSN
Ascendis Pharma stock rating assumed at Overweight by Morgan Stanley - Investing.com
Weekly Stock Grader Analysis: Upgrades & Downgrades on Top Blue-Chip Stocks - InvestorPlace
European ADRs Dip As Biotech Stocks Show Mixed Results - Finimize
Canaccord holds Ascendis Pharma stock at $84 target - Investing.com
BofA raises Ascendis Pharma stock target to $216 - Investing.com
Ascendis Pharma ADR Scores Relative Strength Rating Upgrade - MSN
Ascendis Pharma A S Adr Stock (ASND) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.10%
1.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):